bay1067197
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT01945606)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Adenosine A1 receptorAGONIST
ADORA1 agonist
Partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOc1ccc(-c2c(C#N)c(SCc3csc(-c4ccc(Cl)cc4)n3)nc(N3CCCC3)c2C#N)cc1- Mol. weight
- 716.29 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314392 ↗
- ChEMBLCHEMBL3545405 ↗
Also known as
- bay1067197
- bay1067197
- bay-1067197
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02040233 | Phase 2 | Jan 1, 2014 | Bayer |
| NCT01945606 | Phase 2 | Nov 1, 2013 | Bayer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 2 | 2 | 1 | 2013 |
1 organizations
Page 1 / 1